Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting IL-1β as an immunopreventive and therapeutic modality for K-ras-mutant lung cancer.
Yuan B, Clowers MJ, Velasco WV, Peng S, Peng Q, Shi Y, Ramos-Castaneda M, Zarghooni M, Yang S, Babcock RL, Chang SH, Heymach JV, Zhang J, Ostrin EJ, Watowich SS, Kadara H, Moghaddam SJ. Yuan B, et al. Among authors: kadara h. JCI Insight. 2022 Jun 8;7(11):e157788. doi: 10.1172/jci.insight.157788. JCI Insight. 2022. PMID: 35471938 Free PMC article.
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.
Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, Oborn CJ, Park YY, Erez B, Jacoby JJ, Lee JS, Lin HY, Ciardiello F, Herbst RS, Langley RR, Heymach JV. Cascone T, et al. Among authors: kadara h. J Clin Invest. 2011 Apr;121(4):1313-28. doi: 10.1172/JCI42405. Epub 2011 Mar 23. J Clin Invest. 2011. PMID: 21436589 Free PMC article.
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Skoulidis F, et al. Among authors: kadara h. Cancer Discov. 2015 Aug;5(8):860-77. doi: 10.1158/2159-8290.CD-14-1236. Epub 2015 Jun 11. Cancer Discov. 2015. PMID: 26069186 Free PMC article.
IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.
Caetano MS, Zhang H, Cumpian AM, Gong L, Unver N, Ostrin EJ, Daliri S, Chang SH, Ochoa CE, Hanash S, Behrens C, Wistuba II, Sternberg C, Kadara H, Ferreira CG, Watowich SS, Moghaddam SJ. Caetano MS, et al. Among authors: kadara h. Cancer Res. 2016 Jun 1;76(11):3189-99. doi: 10.1158/0008-5472.CAN-15-2840. Epub 2016 Apr 1. Cancer Res. 2016. PMID: 27197187 Free PMC article.
Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients.
Parra ER, Behrens C, Rodriguez-Canales J, Lin H, Mino B, Blando J, Zhang J, Gibbons DL, Heymach JV, Sepesi B, Swisher SG, Weissferdt A, Kalhor N, Izzo J, Kadara H, Moran C, Lee JJ, Wistuba II. Parra ER, et al. Among authors: kadara h. Clin Cancer Res. 2016 Dec 15;22(24):6278-6289. doi: 10.1158/1078-0432.CCR-15-2443. Epub 2016 Jun 1. Clin Cancer Res. 2016. PMID: 27252415 Free PMC article.
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS. Kadara H, et al. Ann Oncol. 2017 Jan 1;28(1):75-82. doi: 10.1093/annonc/mdw436. Ann Oncol. 2017. PMID: 27687306 Free PMC article.
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.
Choi M, Kadara H, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Kim K, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Herbst RS, Wistuba II. Choi M, et al. Among authors: kadara h. Ann Oncol. 2017 Jan 1;28(1):83-89. doi: 10.1093/annonc/mdw437. Ann Oncol. 2017. PMID: 28177435 Free PMC article.
The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
Cascone T, Xu L, Lin HY, Liu W, Tran HT, Liu Y, Howells K, Haddad V, Hanrahan E, Nilsson MB, Cortez MA, Giri U, Kadara H, Saigal B, Park YY, Peng W, Lee JS, Ryan AJ, Jüergensmeier JM, Herbst RS, Wang J, Langley RR, Wistuba II, Lee JJ, Heymach JV. Cascone T, et al. Among authors: kadara h. Clin Cancer Res. 2017 Sep 15;23(18):5489-5501. doi: 10.1158/1078-0432.CCR-16-3216. Epub 2017 May 30. Clin Cancer Res. 2017. PMID: 28559461 Free PMC article.
Development of Kras mutant lung adenocarcinoma in mice with knockout of the airway lineage-specific gene Gprc5a.
Fujimoto J, Nunomura-Nakamura S, Liu Y, Lang W, McDowell T, Jakubek Y, Ezzeddine D, Kapere Ochieng J, Petersen J, Davies G, Fukuoka J, Wistuba II, Ehli E, Fowler J, Scheet P, Kadara H. Fujimoto J, et al. Among authors: kadara h. Int J Cancer. 2017 Oct 15;141(8):1589-1599. doi: 10.1002/ijc.30851. Epub 2017 Jul 17. Int J Cancer. 2017. PMID: 28653505 Free PMC article.
125 results